Olaparib Review Renews Debate On Maintenance Therapy Endpoints
Executive Summary
Oncologic Drugs Advisory Committee members divided on whether progression-free survival endpoint in AstaZeneca’s Phase III SOLO-2 trial could be used to support approval for maintenance therapy in relapsed ovarian cancer.